Výsledky vyhledávání - "John M. Ebos"

Supplemental Table S1 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Supplementary Table S1. A, Patient characteristics included in the study (Fig. 7, A and B). B, Patient characteristics included in the study (Fig. 7, C and D).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd1dff86394c853dd50115b9ce7db640
https://doi.org/10.1158/0008-5472.22415516.v1

Zobrazit plný text záznamu

Supplemental Figure S7 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Supplementary Figure S7: Recapitulated schema.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c139f5887e86d5e2e2d805f60be3d0ea
https://doi.org/10.1158/0008-5472.22415519

Zobrazit plný text záznamu

Supplemental Figure S1 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Supplementary Figure S1. Tyrosine kinase Inhibitor stimulated VEGFC expression. Tyrosine kinase inhibitors stimulate VEGFC expression in RCC cell lines and primary RCC cells but not in normal cells.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c3868a82f6a51fdb76d90fe297d28ff
https://doi.org/10.1158/0008-5472.22415540.v1

Zobrazit plný text záznamu

Supplemental Figure S5 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Supplementary Figure S5. Overexpression of VEGFC correlated with reduced overall survival of RCC patients. Analysis of in silico available data bases (TCGA Research Network) showed that overexpression of VEGFC is associated with a poor prognosis.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fea6e28172939a869e5d5ba778fcfe7
https://doi.org/10.1158/0008-5472.22415528

Zobrazit plný text záznamu

Supplemental Figure S3 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Supplementary Figure S3. Sorafenib stimulated VEGFC promoter activity, increased the VEGFC mRNA half-life and HuR and TTP bind the 3'UTR of VEGFC and VEGFA mRNA. Sorafenib-dependent induction of VEGFC expression is linked to increased transcription a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48b4fea66b46c4575d2278e6bd8fc310
https://doi.org/10.1158/0008-5472.22415534.v1

Zobrazit plný text záznamu

Supplemental Figure S6 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Supplementary Figure S6. Overexpression of VEGFC correlated with reduced overall survival of RCC patients. A, Kaplan-Meier survival curves of metastatic (M1) RCC patients with high or low VEGFC mRNA expression. These results are in whole or in part b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01de6a97a424a1e6d6c04b987eae48f5
https://doi.org/10.1158/0008-5472.22415522

Zobrazit plný text záznamu

Supplemental Figure S4 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Supplementary Figure S4. Sunitinib does not modified blood vessels. Blood vessels in experimental and patients' tumors are not normalized by sunitinib (equal coverage of CD31 labeled cells by alpha SMA labeled cells).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32ad49bf2242f44be95755e021d32a4f
https://doi.org/10.1158/0008-5472.22415531

Zobrazit plný text záznamu

Data from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Sunitinib is an antiangiogenic therapy given as a first-line treatment for renal cell carcinoma (RCC). While treatment improves progression-free survival, most patients relapse. We hypothesized that patient relapse can stem from the development of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef39c1afc1b5ebe0b2b9bdf34ee7c90a
https://doi.org/10.1158/0008-5472.c.6509306.v1

Zobrazit plný text záznamu

Supplementary Figure Legends from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Legends for supplemental figures

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf35b5ceb65dea288c02ea88dc6409cc
https://doi.org/10.1158/0008-5472.22415513.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání